Vantage Consulting Group Inc Nektar Therapeutics Transaction History

Vantage Consulting Group Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$0.64 - $3.15 $9,162 - $45,095	14,316 Added 121.83%	26,067 $18,000
Q4 2022 Feb 13, 2023	BUY	$2.03 - $4.28 $23,854 - $50,294	11,751 New	11,751 $26,000
Q2 2022 Aug 09, 2022	BUY	$3.17 - $6.17 $33,833 - $65,852	10,673 New	10,673 $41,000
Q1 2021 May 14, 2021	SELL	$16.56 - $25.46 $18,182 - $27,955	-1,098 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$15.77 - $19.03 $17,315 - $20,894	1,098 New	1,098 $19,000

152

130M

92.7K

4.9K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $157M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Vantage Consulting Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vantage Consulting Group Inc with notifications on news.